ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...